Cost-Effective Alternatives to Linaclotide for Constipation Management

First-Line Treatment Options

The American Gastroenterological Association recommends starting with over-the-counter polyethylene glycol (PEG) 17g daily as the most cost-effective first-line alternative, with a cost of $10-45/month 1, 2
PEG has proven efficacy and excellent cost-effectiveness, with a durable response over 6 months 1, 2
Magnesium oxide is also a viable option at 400-500mg daily, costing less than $50/month, but should be used with caution in patients with renal insufficiency 1, 2
Lactulose is another option at 15g daily, costing less than $50/month, and is the only osmotic agent studied in pregnancy 1, 2

Bisacodyl can be used as a short-term or rescue therapy at 5mg daily, with a maximum dose of 10mg daily, costing less than $50/month 1, 2
Senna is also an option at 8.6-17.2mg daily, costing less than $50/month, but its long-term safety and efficacy are unknown 1, 2

Lubiprostone is a more affordable prescription secretagogue option at $374/month, compared to linaclotide at $523/month, and can be used at a dose of 24μg twice daily 1, 2, 3, 4, 5, 6
Lubiprostone improves stool frequency and consistency, as well as abdominal discomfort and bloating, with effects manifesting within 2 days among responders 3, 4, 5, 6
The mechanism of action of lubiprostone involves activating type 2 chloride channels on epithelial cells, increasing intestinal chloride secretion 3, 4, 5, 6
Common side effects of lubiprostone include nausea, which is typically mild or moderate, and can be mitigated by taking the medication with food and water 3, 4, 5, 6

The initial approach involves starting with PEG 17g daily, titrating up to response 1, 2
If there is an inadequate response, magnesium oxide 400-500mg daily can be added or used as an alternative, if there is no renal insufficiency 1, 2
Bisacodyl 5-10mg can be used as needed for short-term relief 1, 2
If over-the-counter agents fail, lubiprostone 24μg twice daily can be considered as the most cost-effective prescription secretagogue option 3, 4, 5, 6, 1, 2

The certainty of evidence for lubiprostone is lower (low overall certainty) compared to linaclotide (moderate overall certainty) 3, 4, 5, 6
Fiber supplementation (soluble fiber) can be added at any stage, but adequate hydration is essential as fiber intake increases 2
Combination therapy is reasonable, with over-the-counter agents able to be combined with prescription secretagogues 4, 5, 6

In patients with chronic constipation who have not responded to optimized linaclotide therapy, the overall certainty of evidence supporting lubiprostone is low, whereas the evidence for linaclotide is of moderate to high certainty; nevertheless, clinical guidelines endorse lubiprostone as a recommended next‑line option when linaclotide fails. 7